Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Core Insights - Cognition Therapeutics, Inc. announced topline results from the SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies, which will be presented by Dr. James E. Galvin at the International Lewy Body Dementia Conference [1][2] Study Results - The Phase 2 SHIMMER study involved 130 adults with mild-to-moderate DLB, showing zervimesine-treated participants scored an average of 86% better on the neuropsychiatric inventory (NPI) A-L compared to placebo [2][5] - Zervimesine-treated participants preserved 52% more ability in activities of daily living (ADCS-ADL) and experienced a 91% reduction in cognitive fluctuations [3][5] - Improvements in motor function were also noted, with zervimesine-treated patients maintaining 62% better motor function than those on placebo [3][5] Safety and Tolerability - The SHIMMER study demonstrated a favorable safety and tolerability profile for zervimesine, with most treatment-related adverse events being mild or moderate [4][5] Study Design - The SHIMMER study was a double-blind, placebo-controlled trial that randomized participants to receive either zervimesine (100 mg or 300 mg) or placebo for six months [8] - The study was supported by a grant from the National Institute on Aging totaling approximately $30 million [9] About Zervimesine - Zervimesine is an experimental small molecule designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 receptor complex, which is involved in regulating cellular processes disrupted in neurodegenerative diseases [10] Company Overview - Cognition Therapeutics, Inc. focuses on developing therapeutics for age-related degenerative disorders of the central nervous system and retina, with ongoing clinical programs in dementia with Lewy bodies and Alzheimer's disease [11]